DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Omapatrilat
Omapatrilat
WHO Drug Information Vol. 12, No. 3, 1998
Next Generation Multifunctional Angiotensin Receptor Blockers
Combined Neprilysin and Renin–Angiotensin System Inhibition in Heart Failure with Reduced Ejection Fraction: a Meta-Analysis
Narrative Review in the Current Role of Angiotensin Receptor- Neprilysin Inhibitors
Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact
207620Orig1s000
Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
Vasopeptidase Inhibition with Omapatrilat in Chronic Heart Failure: Acute and Long-Term Hemodynamic and Neurohumoral Effects Dougal R
Telmisartan Versus Angiotension-Converting
Vasopeptidase Inhibition Restores Renovascular Endothelial Dysfunction in Salt-Induced Hypertension
Reacciones Adversas Causadas Por Fármacos Activos En El Sistema Renina Angiotensina Aldosterona: Descripción De Un Nuevo Síndrome
Vasopeptidase Inhibition: a New Treatment Approach for Endothelial Dysfunction
Neprilysin Inhibition with Sacubitril/Valsartan in the Treatment of Heart Failure
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure Data Supplement
Dual ACE/NEP Inhibitors – More Than Playing the ACE Card
Characterisation of the Pharmacological Actions in Humans of Multiple Vasoactive Enzyme Inhibitors with Therapeutic Potential in Heart Failure
A Review and Guide on the Use of Sacubitril/Valsartan
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: a Randomised Double-Blind Trial
Top View
First-Line Combination Therapy Versus First-Line Monotherapy for Primary Hypertension (Review)
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Angioedema Spotlight: a Closer Examination of Sacubitril/Valsartan Safety Results
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Comparison of the Effects of an Angiotensin-Converting Enzyme
Vasopeptidase Inhibition: Cardiovascular Therapy for the New Millennium?
Omapatrilat for the Management of Heart Failure and Hypertension
Omapatrilat, an Angiotensin-Converting Enzyme
An Application to Include Blood Pressure Lowering Drug Fixed Dose
Effects of Captopril and Omapatrilat on Early Post-Myocardial Infarction Survival and Cardiac Hemodynamics in Rats: Interaction with Cardiac Cytokine Expression
Cardioprotective Effects of Vasopeptidase Inhibition Vs
Hypertension: LCZ696, a Novel Dual Inhibitor of Neprilysin and the Angiotensin II Receptor, Shows Promise in Phase II Trial
Exercise Tolerance and Morbidity in Patients with Heart Failure: IMPRESS Randomised Trial